180330-54-5

Upstream product

• 609-65-4 o-chlorobenzoyl chloride 
• 56-40-6 glycine 
• 31407-28-0 amino-2 carboxamido-3 quinoleine 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 199787-23-0 5-O-(4-chlorobenzoyl)-1,2,3-tri-O-(4-toluoyl)-3-C-(2-trimethylsilylethynyl)-α,β-D-ribofuranose 
• 199787-22-9 1,2,3-tri-O-benzoyl-5-O-(4-chlorobenzoyl)-3-C-(2-trimethylsilylethynyl)-α,β-D-ribofuranose 
• 55583-59-0 2,5-diamino-4,6-dichloropyrimidine 
• 138812-69-8 (S)-4-(benzyloxycarbonyl)piperazine-2-carboxylic acid 
• 151719-72-1 1-<3-(acetylamino)-4-(3-chloropropoxy)phenyl>ethanone 
• 114927-11-6 N(4-aminobenzoyl)-L-methionine 
• 103577-45-3 lansoprasole 
• 337471-15-5 cis-4b,5,9b,10-Tetrahydro-3,7-dinitroindeno[1,2-b]indole 
• 122024-61-7 benzyl 3-benzyloxy-5-methoxy-1-benzo[b]thiophene-2-carboxylate 
• 131741-28-1 6-[4-(1,1-dicyanomethylidene-N-methylhydrazino)phenyl]-4,5-dihydro-5-methylpyridazin-3(2H)one 
• 73783-05-8 p-[2-(cyclopentyl)ethylamino]phenylacetic acid 
• 118696-05-2 2-(3-chlorophenyl)-3H-imidazo[4,5-b]pyridine-3-acetic acid 
• 362-05-0 2-Hydroxyestradiol 
• 28511-78-6 4-nitro-N-(1-phenyl-pyrrolidin-3-yl)-benzamide 

Relevant academic research and scientific papers

6-substituted purine carbocyclic nucleosides

The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of comp

Terminated bis(3,4-dicyanophenoxy) alkanes

Terminated bis(3,4-dicyanophenoxy) alkanes, wherein the alkylene chain is om 2 to 30 carbon atoms in length, is prepared by the reaction of 4-nitrophthalonitrile with a terminated alkane diol at elevated temperatures. A polyphthalocyanine resin is obtaine

Pharmaceutical compositions and methods of using the same

The present application relates to pharmaceutical compositions incorporating as active ingredient p.chlorohippuric acid or one of its mineral or organic base addition salts. The pharmaceutical compositions are those adapted for parenteral or oral administration. They may include another active ingredient. The present application also extends to therapeutic methods for using the said pharmaceutical compositions namely for protecting the gastric mucosa from acid hypersecretion, ulcers from therapeutic origin and for protecting the liver from toxic aggressions.

Fused pyrimidin-4(3H)-ones as antiallergy agents

Fused heterocyclic ring systems in which a quinoline or a pyridine component is "fused" to a pyrimidine having a 2-methyl, 2-ethyl, or 2-acetyl group and a 4-keto group, and to similar ring systems in which a quinoline, a naphthalene or a pyridine component is "fused" to a pyrimidine having a 2-carboxy group and a 4-keto group, derivatives, and pharmaceutically-acceptable cationic salts thereof, and their use as antiallergy agents, and intermediates therefor.